Journal of Scientific Dentistry

Register      Login

VOLUME 8 , ISSUE 1 ( January-June, 2018 ) > List of Articles


Pentoxifylline Therapy in the Management of Oral Submucous Fibrosis – A Review

Khaaviya N, Fahmitha Parveen S, Vezhavendhan N, Sivaramakrishnan M

Citation Information : N K, S FP, N V, M S. Pentoxifylline Therapy in the Management of Oral Submucous Fibrosis – A Review. 2018; 8 (1):19-21.

DOI: 10.5005/jsd-8-1-19

License: CC BY-NC 4.0

Published Online: 20-08-2020

Copyright Statement:  Copyright © 2018; The Author(s).


Aim: Oral sub mucous fibrosis is a high risk pre malignant condition predominantly seen in the Indian subcontinent. The aim of the study was to review the effect of Pentoxifylline on the clinical and pathologic course of OSMF. Material and methods: A review study was done to analyse the efficacy of Pentoxifylline in the treatment of OSMF. We searched over PubMed and Google database for studies meeting our eligibility criteria (august 2006 to July 2017). A total of 270 patients who were clinically diagnosed as OSMF from a total of 6 studies with one meta-analyses, 2 randomized control trial, three clinical trials were included for this review. Results: Pentoxifylline is a methyxanthine derivative, which showed considerable improvement in mouth opening, tongue protrusion, difficulty in speech and swallowing. The total symptom score improved by 85.8% in Pentoxifylline. Dexamethasone and Pentoxifylline showed significant mouth opening and reduction in burning sensation. Conclusion: Pentoxifylline can bring about significant improvement in all clinical signs of maximal mouth opening, tongue protrusion, burning sensation thereby improving the quality of life. Conflicting to the above findings, one randomized clinical trial showed no significant advancement in burning sensation, mouth opening, tongue protrusion.

PDF Share
  1. Liu J, Chen F, Wei Z, Qiu M, Li Z, Dan H, Chen Q, Jiang L. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis. Oral Dis. 2018;24(5):706- 716.
  2. Namdeo prabhu, Sanjay S rao, S M kotrashetti, Shridhar D Baliga, Seema R Hallikerimath, Punnya V Angadi and Rakhi Issrani. Pentoxifylline in patients with oral submucous fibrosis- A randomized clinical trial. J Maxillofacial Oral Surg. 2013;14(1)81-89.
  3. Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res [serial online] 2006 [cited 2019 Jan 22];17:190-8.
  4. Santhosh patil, Sneha Maheswari. Efficacy of pentoxifylline in the management of oral submucous fibrosis. Journal of orofacial sciences vol:6 2014: 94-98.
  5. Patil S, Maheshwari S. Efficacy of pentoxifylline in the management of oral submucous fibrosis. J Orofac Sci 2014;6:94-8.
  6. Ravi Mehrotra, HP Singh, SC Gupta, M Singh, S Jain. Pentoxifylline therapy in the management of oral submucous fibrosis. Asian pacific journal of cancer prevention 2011;12(4):971-74.
  7. Jayachandran Sadaksharam, Sureshkumar Mahalingam. Pentoxifylline therapy: Evaluation of oral pentoxifylline in the management of oral submucous fibrosis – An ultrasonographic study. Contemp Clin Dent. 2017 Apr-Jun; 8(2): 200–204.
  8. Berman B, Wietzerbin J, Sancean J et al: Pentoxifylline inhibits certain constitutive and tumor necrosis factor-a induced activities of human normal dermal fibroblasts, J Invest Dermatol 98: 706-12, 1992.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.